TY - JOUR
T1 - Cardiovascular magnetic resonance in rheumatology
T2 - Current status and recommendations for use
AU - Mavrogeni, Sophie I.
AU - Kitas, George D.
AU - Dimitroulas, Theodoros
AU - Sfikakis, Petros P.
AU - Seo, Philip
AU - Gabriel, Sherine
AU - Patel, Amit R.
AU - Gargani, Luna
AU - Bombardieri, Stefano
AU - Matucci-Cerinic, Marco
AU - Lombardi, Massimo
AU - Pepe, Alessia
AU - Aletras, Anthony H.
AU - Kolovou, Genovefa
AU - Miszalski, Tomasz
AU - Van Riel, Piet
AU - Semb, Annegrete
AU - Gonzalez-Gay, Miguel Angel
AU - Dessein, Patrick
AU - Karpouzas, George
AU - Puntman, Valentina
AU - Nagel, Eike
AU - Bratis, Konstantinos
AU - Karabela, Georgia
AU - Stavropoulos, Efthymios
AU - Katsifis, Gikas
AU - Koutsogeorgopoulou, Loukia
AU - Van Rossum, Albert
AU - Rademakers, Frank
AU - Pohost, Gerald
AU - Lima, Joao A.C.
N1 - Publisher Copyright:
© 2016 Published by Elsevier Ireland Ltd.
PY - 2016/8/15
Y1 - 2016/8/15
N2 - Targeted therapies in connective tissue diseases (CTDs) have led to improvements of disease-associated outcomes, but life expectancy remains lower compared to general population due to emerging co-morbidities, particularly due to excess cardiovascular risk. Cardiovascular magnetic resonance (CMR) is a noninvasive imaging technique which can provide detailed information about multiple cardiovascular pathologies without using ionizing radiation. CMR is considered the reference standard for quantitative evaluation of left and right ventricular volumes, mass and function, cardiac tissue characterization and assessment of thoracic vessels; it may also be used for the quantitative assessment of myocardial blood flow with high spatial resolution and for the evaluation of the proximal coronary arteries. These applications are of particular interest in CTDs, because of the potential of serious and variable involvement of the cardiovascular system during their course. The International Consensus Group on CMR in Rheumatology was formed in January 2012 aiming to achieve consensus among CMR and rheumatology experts in developing initial recommendations on the current state-of-the-art use of CMR in CTDs. The present report outlines the recommendations of the participating CMR and rheumatology experts with regards to: (a) indications for use of CMR in rheumatoid arthritis, the spondyloarthropathies, systemic lupus erythematosus, vasculitis of small, medium and large vessels, myositis, sarcoidosis (SRC), and scleroderma (SSc); (b) CMR protocols, terminology for reporting CMR and diagnostic CMR criteria for assessment and quantification of cardiovascular involvement in CTDs; and (c) a research agenda for the further development of this evolving field.
AB - Targeted therapies in connective tissue diseases (CTDs) have led to improvements of disease-associated outcomes, but life expectancy remains lower compared to general population due to emerging co-morbidities, particularly due to excess cardiovascular risk. Cardiovascular magnetic resonance (CMR) is a noninvasive imaging technique which can provide detailed information about multiple cardiovascular pathologies without using ionizing radiation. CMR is considered the reference standard for quantitative evaluation of left and right ventricular volumes, mass and function, cardiac tissue characterization and assessment of thoracic vessels; it may also be used for the quantitative assessment of myocardial blood flow with high spatial resolution and for the evaluation of the proximal coronary arteries. These applications are of particular interest in CTDs, because of the potential of serious and variable involvement of the cardiovascular system during their course. The International Consensus Group on CMR in Rheumatology was formed in January 2012 aiming to achieve consensus among CMR and rheumatology experts in developing initial recommendations on the current state-of-the-art use of CMR in CTDs. The present report outlines the recommendations of the participating CMR and rheumatology experts with regards to: (a) indications for use of CMR in rheumatoid arthritis, the spondyloarthropathies, systemic lupus erythematosus, vasculitis of small, medium and large vessels, myositis, sarcoidosis (SRC), and scleroderma (SSc); (b) CMR protocols, terminology for reporting CMR and diagnostic CMR criteria for assessment and quantification of cardiovascular involvement in CTDs; and (c) a research agenda for the further development of this evolving field.
KW - Cardiovascular magnetic resonance imaging
KW - Rheumatic diseases
UR - http://www.scopus.com/inward/record.url?scp=84966441202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966441202&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2016.04.158
DO - 10.1016/j.ijcard.2016.04.158
M3 - Review article
C2 - 27179903
AN - SCOPUS:84966441202
SN - 0167-5273
VL - 217
SP - 135
EP - 148
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -